STOMACH NEOPLASMNCT07828899
Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
A study testing Single-Port Robot-Assisted Radical Distal Gastrectomy and Multi-Port Robot-Assisted Radical Distal Gastrectomy in people with STOMACH NEOPLASM and Robotic Surgical Procedures, run by First Affiliated Hospital of Wenzhou Medical University at 5 sites in China.
Trial summary
This multicenter randomized non-inferiority trial evaluates single-port versus multi-port robotic-assisted radical distal gastrectomy in patients with gastric cancer. A prespecified prospective substudy will assess early postoperative pain, abdominal wall trauma, and early recovery between the two surgical approaches. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- STOMACH NEOPLASM, Robotic Surgical Procedures
- What is being tested?
- Single-Port Robot-Assisted Radical Distal Gastrectomy and Multi-Port Robot-Assisted Radical Distal Gastrectomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 212 participants
- Where
- 5 sitesChina
- Study dates
- Oct 2026to Nov 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18-85 years, irrespective of sex.
- Histologically confirmed primary gastric adenocarcinoma based on endoscopic biopsy.
- The primary tumor is located in the middle or distal third of the stomach, or at another site considered amenable to radical distal gastrectomy. Preoperative evaluation indicates that robot-assisted radical distal gastrectomy is technically feasible and that an R0 resection is anticipated. Patients who have received standard neoadjuvant therapy may also be eligible if reassessment confirms fulfillment of the above surgical criteria.
- Clinical stage cT1-3N0-1M0 according to the 8th edition of the AJCC TNM staging system for gastric cancer, as assessed by gastroscopy and contrast-enhanced computed tomography of the chest, abdomen, and pelvis, with endoscopic ultrasonography, abdominal magnetic resonance imaging, or diagnostic laparoscopy performed when clinically indicated. Preoperative assessment should indicate that R0 resection can be achieved by distal gastrectomy, with no evidence of adjacent organ invasion or distant metastasis.
- No history of other malignancies within the preceding 5 years, except for adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, or other malignancies with a similarly negligible risk of recurrence.
- American Society of Anesthesiologists (ASA) physical status class I-III.
Show all 9Show fewer
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1.
- Adequate major organ function, with preoperative assessment confirming fitness for general anesthesia and robot-assisted radical distal gastrectomy.
- Subjects voluntarily participate in the study, fully understand the trial protocol and provide written informed consent.
Who cannot join
- Body mass index (BMI) >35 kg/m².
- Previous gastrectomy, or a history of major upper abdominal surgery considered likely to substantially compromise the feasibility or safety of robot-assisted distal gastrectomy, such as complex hepatobiliary-pancreatic surgery or surgery involving the esophagogastric junction. Previous uncomplicated laparoscopic cholecystectomy, appendectomy, or similar procedures are not, in principle, considered exclusionary.
- Tumor-related acute obstruction, active major hemorrhage, or perforation requiring emergency surgery.
- Preoperative confirmation of synchronous multiple gastric cancers or remnant gastric cancer, or the presence or history within the preceding 5 years of another active malignancy that may interfere with study treatment or assessment of study endpoints.
- Preoperative assessment indicating that radical distal gastrectomy is oncologically or technically inappropriate, including anticipated requirement for total gastrectomy, proximal gastrectomy, combined esophagectomy, or any other procedure other than distal gastrectomy.
- Preoperative evaluation or diagnostic laparoscopy demonstrating definite invasion of adjacent organs requiring en bloc multivisceral resection; distant metastasis, including peritoneal, hepatic, pulmonary, osseous, or distant lymph-node metastasis; or positive peritoneal lavage cytology.
Show all 12Show fewer
- Standard preoperative evaluation indicating that the patient is not currently an appropriate candidate for upfront radical distal gastrectomy and requires initiation or continuation of neoadjuvant therapy or other antineoplastic treatment.
- Concomitant disease requiring an additional surgical procedure at the time of radical gastrectomy that may substantially affect operative duration, perioperative safety, postoperative recovery, or assessment of the primary endpoint.
- Pregnancy or lactation, or planned pregnancy during the study period.
- Severe cardiac, pulmonary, hepatic, or renal dysfunction; severe coagulation abnormalities; uncontrolled infection; or any other medical condition considered to preclude safe administration of general anesthesia or surgical treatment.
- Inability to provide valid informed consent because of cognitive impairment, psychiatric or mental status abnormalities, or other reasons, or inability to comply with protocol-specified treatment and follow-up procedures.
- Any other condition that, in the investigator's judgment, renders the patient unsuitable for participation in the study.
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
China5 sites
Beijing Tsinghua Changgung Hospital
Beijing
Guoxin Li
PLA Army Characteristic Medical Center
Chongqing
Fan Li
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong
Leping Li
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei
Qun Zhao
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000
About this study
Official title: Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer: a Multicenter, Prospective, Open-Label, Randomized Controlled Trial
This multicenter randomized non-inferiority trial evaluates single-port versus multi-port robotic-assisted radical distal gastrectomy in patients with gastric cancer. A prespecified prospective substudy will assess early postoperative pain, abdominal wall trauma, and early recovery between the two surgical approaches.
- Conditions
- STOMACH NEOPLASM, Robotic Surgical Procedures
- Being tested
- Single-Port Robot-Assisted Radical Distal Gastrectomy, Multi-Port Robot-Assisted Radical Distal Gastrectomy
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Single-Port Robot-Assisted Radical Distal GastrectomyProcedure or surgery
Participants assigned to this intervention will undergo robot-assisted radical distal gastrectomy using a single-port surgical approach. The surgical procedure will be performed according to the predefined study protocol.
Multi-Port Robot-Assisted Radical Distal GastrectomyProcedure or surgery
Participants assigned to this intervention will undergo robot-assisted radical distal gastrectomy using a multi-port surgical approach. The surgical procedure will be performed according to the predefined study protocol.
| Study group | Role | What they receive |
|---|---|---|
| Single-Port Robotic Gastrectomy Group | Experimental | Participants randomized to this group will undergo single-port robot-assisted radical distal gastrectomy for distal gastric cancer according to the predefined study protocol Receives: Procedure: Single-Port Robot-Assisted Radical Distal Gastrectomy |
| Multi-Port Robotic Gastrectomy Group | Active comparator | Participants randomized to this group will undergo conventional multi-port robot-assisted radical distal gastrectomy for distal gastric cancer according to the predefined study protocol Receives: Procedure: Multi-Port Robot-Assisted Radical Distal Gastrectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Technical Success of the Randomly Assigned Robotic Surgical Approach
Technical success is defined as completion of the protocol-specified gastrectomy, lymph node dissection, and gastrointestinal reconstruction using the robotic surgical approach assigned at randomization. In the single-port group, technical success requires completion using the single-port robotic system without conversion to multi-port robotic surgery, conventional laparoscopic surgery, or open surgery, and without any unplanned additional port beyond those permitted by the protocol. In the multi-port group, technical success requires completion using the multi-port robotic system without conversion to conventional laparoscopic surgery or open surgery. Failure to complete the assigned robotic procedure because of participant-related, operative, or device-related reasons will be classified as technical failure. The prespecified noninferiority margin is -10 percentage points.
Measured: At the end of surgery
Secondary outcomes (28)
Total Operative Time
Total duration of the surgical procedure, recorded in minutes according to the protocol-defined timing criteria.
Measured: Intraoperative
Robotic Docking Time
Duration required for robotic docking, recorded in minutes according to the protocol-defined timing criteria.
Measured: Intraoperative
Robotic Console Time
Duration of robotic console operation, recorded in minutes according to the protocol-defined timing criteria.
Measured: Intraoperative
Intraoperative Blood Loss
Estimated volume of blood loss during surgery, recorded in milliliters.
Measured: Intraoperative
Percentage of Participants With Intraoperative Complications
Intraoperative complications will be recorded and graded according to the Satava classification system.
Measured: Intraoperative
Percentage of Participants With R0 Resection
R0 resection is defined as complete tumor resection with no microscopic residual tumor at the resection margins, as determined by postoperative pathological examination.
Measured: At completion of postoperative pathological assessment, within 30 days after surgery
Number of Lymph Nodes Retrieved
Total number of lymph nodes retrieved and identified during postoperative pathological examination.
Measured: At completion of postoperative pathological assessment, within 30 days after surgery
Number of Metastatic Lymph Nodes
Total number of pathologically confirmed metastatic lymph nodes identified during postoperative pathological examination.
Measured: At completion of postoperative pathological assessment, within 30 days after surgery
Overall postoperative complications
Any postoperative complication occurring from the end of surgery through postoperative Day 30 will be recorded according to the predefined study protocol and graded using the Clavien-Dindo classification.
Measured: From the end of surgery through 30 days after surgery
Percentage of Participants With Clavien-Dindo Grade III or Higher Postoperative Complications
Severe postoperative complications are defined as postoperative complications classified as Clavien-Dindo Grade III or higher.
Measured: From the end of surgery through 30 days after surgery
Specific surgery-related complications
Prespecified surgery-related complications include anastomotic leakage, anastomotic bleeding or stenosis, duodenal stump leakage, pancreatic fistula or postoperative pancreatitis, intra-abdominal bleeding, intra-abdominal infection or abscess, bile leakage, chylous or lymphatic leakage, delayed gastric emptying, postoperative ileus or bowel obstruction, internal hernia, bowel perforation or ischemic necrosis, and wound complications requiring clinical intervention.
Measured: From the end of surgery through 30 days after surgery
Percentage of Participants With Unplanned Reoperation Within 30 Days After Surgery
Percentage of participants requiring an unplanned surgical reoperation for any postoperative reason within 30 days after the index surgery.
Measured: Within 30 days after surgery
Percentage of Participants With Unplanned Readmission Within 30 Days After Surgery
Percentage of participants requiring an unplanned hospital readmission within 30 days after the index surgery.
Measured: Within 30 days after surgery
Percentage of Participants Who Die Within 30 Days After Surgery
All-cause mortality occurring within 30 days after the index surgery.
Measured: Within 30 days after surgery
Pain and Early Recovery Substudy: Estimated Marginal Mean Resting VAS Pain Score Across Postoperative Days 1-3
This is the prespecified primary outcome of the embedded postoperative pain and early recovery substudy, which is planned to include 140 participants from the parent randomized trial. Resting postoperative pain will be assessed using the Visual Analog Scale (VAS) on postoperative Days 1, 2, and 3 according to a standardized assessment procedure. For the primary analysis, a linear mixed-effects model for repeated measures will be applied, adjusting for pre-specified confounding factors including study site. It will estimate the overall mean resting VAS score across postoperative Days 1-3 for each group, together with the between-group difference and its 95% confidence interval. Higher VAS scores indicate greater pain intensity. The prespecified superiority hypothesis evaluates whether the overall resting VAS pain level across postoperative Days 1-3 is lower in the single-port group than in the multi-port group.
Measured: Postoperative Days 1 through 3
Pain and Early Recovery Substudy: Resting VAS Pain Score at 6 Hours After Surgery
This is a prespecified supportive outcome of the embedded postoperative pain and early recovery substudy. Resting postoperative pain will be assessed using the Visual Analog Scale (VAS) at 6 hours after surgery according to the standardized assessment procedure. Higher VAS scores indicate greater pain intensity.
Measured: 6 hours after surgery
Pain and Early Recovery Substudy: Resting VAS Pain Score on Postoperative Day 1
This is a prespecified time-point-specific supportive outcome of the embedded postoperative pain and early recovery substudy. Resting postoperative pain will be assessed using the Visual Analog Scale (VAS) on postoperative Day 1 according to the standardized assessment procedure. VAS scores on postoperative Day 1 will be analyzed separately to compare pain intensity between the single-port and multi-port groups. Where appropriate, estimated marginal means and the between-group difference at postoperative Day 1 will be derived from the prespecified linear mixed-effects model. Multiplicity adjustment will be applied according to the prespecified statistical analysis plan. Higher VAS scores indicate greater pain intensity. This analysis is supportive of the primary longitudinal analysis and does not constitute a separate confirmatory superiority hypothesis.
Measured: Postoperative Day 1
Pain and Early Recovery Substudy: Resting VAS Pain Score on Postoperative Day 2
This is a prespecified time-point-specific supportive outcome of the embedded postoperative pain and early recovery substudy. Resting postoperative pain will be assessed using the Visual Analog Scale (VAS) on postoperative Day 2 according to the standardized assessment procedure. VAS scores on postoperative Day 2 will be analyzed separately to compare pain intensity between the single-port and multi-port groups. Where appropriate, estimated marginal means and the between-group difference at postoperative Day 2 will be derived from the prespecified linear mixed-effects model. Multiplicity adjustment will be applied according to the prespecified statistical analysis plan. Higher VAS scores indicate greater pain intensity. This analysis is supportive of the primary longitudinal analysis and does not constitute a separate confirmatory superiority hypothesis.
Measured: Postoperative Day 2
Pain and Early Recovery Substudy: Resting VAS Pain Score on Postoperative Day 3
This is a prespecified time-point-specific supportive outcome of the embedded postoperative pain and early recovery substudy. Resting postoperative pain will be assessed using the Visual Analog Scale (VAS) on postoperative Day 3 according to the standardized assessment procedure. VAS scores on postoperative Day 3 will be analyzed separately to compare pain intensity between the single-port and multi-port groups. Where appropriate, estimated marginal means and the between-group difference at postoperative Day 3 will be derived from the prespecified linear mixed-effects model. Multiplicity adjustment will be applied according to the prespecified statistical analysis plan. Higher VAS scores indicate greater pain intensity. This analysis is supportive of the primary longitudinal analysis and does not constitute a separate confirmatory superiority hypothesis.
Measured: Postoperative Day 3
Pain and Early Recovery Substudy: Percentage of Participants Requiring Rescue Analgesia
This is a prespecified secondary or supportive outcome of the embedded postoperative pain and early recovery substudy. Rescue analgesia is defined as additional analgesic treatment administered because of inadequate pain control beyond the protocol-specified routine postoperative analgesic regimen. The proportion of participants requiring at least one rescue analgesic intervention during the prespecified postoperative observation period will be recorded and compared between the single-port and multi-port groups. This outcome does not have a separate confirmatory superiority hypothesis.
Measured: From the end of surgery through postoperative Day 3
Pain and Early Recovery Substudy: Cumulative Postoperative Opioid Consumption in Morphine Milligram Equivalents
This is a prespecified secondary or supportive outcome of the embedded postoperative pain and early recovery substudy. All postoperative opioid analgesics administered during the prespecified observation period will be recorded. Individual opioid doses will be converted to morphine milligram equivalents (MME) using a prespecified standardized conversion method, and cumulative MME will be calculated for each participant to allow quantitative comparison of postoperative opioid requirements between the single-port and multi-port groups. This outcome does not have a separate confirmatory superiority hypothesis.
Measured: From the end of surgery through postoperative Day 3
Total Abdominal Wall Incision Length
Total abdominal wall incision length will be calculated as the sum of the lengths of all abdominal surgical incisions and recorded in centimeters according to the standardized study assessment procedure. This outcome will be assessed in randomized participants to compare abdominal wall trauma between the single-port and multi-port robotic surgical groups. It is also included as a prespecified supportive outcome of the embedded postoperative pain and early recovery substudy.
Measured: At the end of surgery
Maximum Length of a Single Abdominal Wall Incision
The length of the longest individual abdominal wall surgical incision will be measured in centimeters according to the standardized study assessment procedure. This outcome will be assessed in randomized participants to compare the extent of abdominal wall trauma between the single-port and multi-port robotic surgical groups. It is also included as a prespecified supportive outcome of the embedded postoperative pain and early recovery substudy.
Measured: At the end of surgery
Time to First Postoperative Flatus
Time to first postoperative flatus is defined as the time from the end of surgery to the first passage of flatus and will be recorded in hours. This outcome will be assessed in randomized participants to compare early postoperative gastrointestinal recovery between the single-port and multi-port robotic surgical groups.
Measured: Up to 30 days after surgery
Time to First Postoperative Defecation
Time to first postoperative defecation is defined as the time from the end of surgery to the first postoperative bowel movement and will be recorded in hours. This outcome will be assessed in randomized participants to compare early postoperative gastrointestinal recovery between the single-port and multi-port robotic surgical groups.
Measured: Up to 30 days after surgery
Time to First Postoperative Ambulation
Time to first postoperative walking lasting more than 5 minutes is defined as the time from the end of surgery to the first postoperative walking episode lasting more than 5 minutes and will be recorded in hours. Brief standing or walking episodes lasting 5 minutes or less will not be considered as meeting this outcome. This outcome will be assessed in randomized participants to compare early postoperative functional recovery between the single-port and multi-port robotic surgical groups. It is also included as a prespecified supportive outcome of the embedded postoperative pain and early recovery substudy.
Measured: Up to 30 days after surgery
Time to First Postoperative Oral Intake
Time to first postoperative oral intake is defined as the time from the end of surgery to the first postoperative oral intake of liquid, soft food, or regular food and will be recorded in days. This outcome will be assessed in randomized participants to compare early postoperative recovery between the single-port and multi-port robotic surgical groups.
Measured: Up to 30 days after surgery
Time to Meeting Discharge Criteria
Time to meeting discharge criteria is defined as the time from the end of surgery until the participant meets all prespecified discharge criteria. These criteria include stable vital signs without fever; recovery of gastrointestinal function with adequate oral intake and no requirement for intravenous nutritional support; ability to ambulate independently without significant discomfort; and satisfactory wound and drainage status with laboratory findings considered clinically acceptable according to the study protocol. This outcome will be assessed in randomized participants to compare early postoperative recovery between the single-port and multi-port robotic surgical groups.
Measured: Up to 30 days after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2026
- Study startOct 2026 (estimated)
- Primary completionOct 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for STOMACH NEOPLASMStudies of the same condition, open and under way.
- More trials run by First Affiliated Hospital of Wenzhou Medical UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 212 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07828899
- Sponsor's protocol ID
- KY2026-423
- Status last verified
- Sep 2026
- First submitted
- 4 Sep 2026
- Last updated
- 18 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer: a Multicenter, Prospective, Open-Label, Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07828899
- Acronym / sponsor ID
- KY2026-423
- Conditions
- STOMACH NEOPLASM, Robotic Surgical Procedures
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 212 participants (estimated)
- Lead sponsor
- First Affiliated Hospital of Wenzhou Medical UniversityUniversity, hospital or other
- Study start
- Oct 2026 (estimated)
- Primary completion
- Oct 2027 (estimated)
- Study completion
- Nov 2027 (estimated)
- First posted
- 18 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multicenter randomized non-inferiority trial evaluates single-port versus multi-port robotic-assisted radical distal gastrectomy in patients with gastric cancer. A prespecified prospective substudy will assess early postoperative pain, abdominal wall trauma, and early recovery between the two surgical approaches.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Single-Port Robotic Gastrectomy Group | Experimental | Procedure: Single-Port Robot-Assisted Radical Distal GastrectomyParticipants randomized to this group will undergo single-port robot-assisted radical distal gastrectomy for distal gastric cancer according to the predefined study protocol |
| Multi-Port Robotic Gastrectomy Group | Active comparator | Procedure: Multi-Port Robot-Assisted Radical Distal GastrectomyParticipants randomized to this group will undergo conventional multi-port robot-assisted radical distal gastrectomy for distal gastric cancer according to the predefined study protocol |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age 18-85 years, irrespective of sex.
- Histologically confirmed primary gastric adenocarcinoma based on endoscopic biopsy.
- The primary tumor is located in the middle or distal third of the stomach, or at another site considered amenable to radical distal gastrectomy. Preoperative evaluation indicates that robot-assisted radical distal gastrectomy is technically feasible and that an R0 resection is anticipated. Patients who have received standard neoadjuvant therapy may also be eligible if reassessment confirms fulfillment of the above surgical criteria.
- Clinical stage cT1-3N0-1M0 according to the 8th edition of the AJCC TNM staging system for gastric cancer, as assessed by gastroscopy and contrast-enhanced computed tomography of the chest, abdomen, and pelvis, with endoscopic ultrasonography, abdominal magnetic resonance imaging, or diagnostic laparoscopy performed when clinically indicated. Preoperative assessment should indicate that R0 resection can be achieved by distal gastrectomy, with no evidence of adjacent organ invasion or distant metastasis.
- No history of other malignancies within the preceding 5 years, except for adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, or other malignancies with a similarly negligible risk of recurrence.
Key exclusion criteria (12 listed)
- Body mass index (BMI) >35 kg/m².
- Previous gastrectomy, or a history of major upper abdominal surgery considered likely to substantially compromise the feasibility or safety of robot-assisted distal gastrectomy, such as complex hepatobiliary-pancreatic surgery or surgery involving the esophagogastric junction. Previous uncomplicated laparoscopic cholecystectomy, appendectomy, or similar procedures are not, in principle, considered exclusionary.
- Tumor-related acute obstruction, active major hemorrhage, or perforation requiring emergency surgery.
- Preoperative confirmation of synchronous multiple gastric cancers or remnant gastric cancer, or the presence or history within the preceding 5 years of another active malignancy that may interfere with study treatment or assessment of study endpoints.
- Preoperative assessment indicating that radical distal gastrectomy is oncologically or technically inappropriate, including anticipated requirement for total gastrectomy, proximal gastrectomy, combined esophagectomy, or any other procedure other than distal gastrectomy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Single-Port Robot-Assisted Radical Distal GastrectomyParticipants assigned to this intervention will undergo robot-assisted radical distal gastrectomy using a single-port surgical approach. The surgical procedure will be performed according to the predefined study protocol. | Procedure or surgery | Single-Port Robotic Gastrectomy Group |
| Multi-Port Robot-Assisted Radical Distal GastrectomyParticipants assigned to this intervention will undergo robot-assisted radical distal gastrectomy using a multi-port surgical approach. The surgical procedure will be performed according to the predefined study protocol. | Procedure or surgery | Multi-Port Robotic Gastrectomy Group |
Primary outcome
Percentage of Participants With Technical Success of the Randomly Assigned Robotic Surgical Approach
Time frame: At the end of surgery
Technical success is defined as completion of the protocol-specified gastrectomy, lymph node dissection, and gastrointestinal reconstruction using the robotic surgical approach assigned at randomization. In the single-port group, technical success requires completion using the single-port robotic system without conversion to multi-port robotic surgery, conventional laparoscopic surgery, or open surgery, and without any unplanned additional port beyond those permitted by the protocol. In the multi-port group, technical success requires completion using the multi-port robotic system without conversion to conventional laparoscopic surgery or open surgery. Failure to complete the assigned robotic procedure because of participant-related, operative, or device-related reasons will be classified as technical failure. The prespecified noninferiority margin is -10 percentage points.
28 secondary outcomes
Total Operative Time
Time frame: Intraoperative
Robotic Docking Time
Time frame: Intraoperative
Robotic Console Time
Time frame: Intraoperative
Intraoperative Blood Loss
Time frame: Intraoperative
Percentage of Participants With Intraoperative Complications
Time frame: Intraoperative
Percentage of Participants With R0 Resection
Time frame: At completion of postoperative pathological assessment, within 30 days after surgery
Number of Lymph Nodes Retrieved
Time frame: At completion of postoperative pathological assessment, within 30 days after surgery
Number of Metastatic Lymph Nodes
Time frame: At completion of postoperative pathological assessment, within 30 days after surgery
Overall postoperative complications
Time frame: From the end of surgery through 30 days after surgery
Percentage of Participants With Clavien-Dindo Grade III or Higher Postoperative Complications
Time frame: From the end of surgery through 30 days after surgery
Specific surgery-related complications
Time frame: From the end of surgery through 30 days after surgery
Percentage of Participants With Unplanned Reoperation Within 30 Days After Surgery
Time frame: Within 30 days after surgery
Percentage of Participants With Unplanned Readmission Within 30 Days After Surgery
Time frame: Within 30 days after surgery
Percentage of Participants Who Die Within 30 Days After Surgery
Time frame: Within 30 days after surgery
Pain and Early Recovery Substudy: Estimated Marginal Mean Resting VAS Pain Score Across Postoperative Days 1-3
Time frame: Postoperative Days 1 through 3
Pain and Early Recovery Substudy: Resting VAS Pain Score at 6 Hours After Surgery
Time frame: 6 hours after surgery
Pain and Early Recovery Substudy: Resting VAS Pain Score on Postoperative Day 1
Time frame: Postoperative Day 1
Pain and Early Recovery Substudy: Resting VAS Pain Score on Postoperative Day 2
Time frame: Postoperative Day 2
Pain and Early Recovery Substudy: Resting VAS Pain Score on Postoperative Day 3
Time frame: Postoperative Day 3
Pain and Early Recovery Substudy: Percentage of Participants Requiring Rescue Analgesia
Time frame: From the end of surgery through postoperative Day 3
Pain and Early Recovery Substudy: Cumulative Postoperative Opioid Consumption in Morphine Milligram Equivalents
Time frame: From the end of surgery through postoperative Day 3
Total Abdominal Wall Incision Length
Time frame: At the end of surgery
Maximum Length of a Single Abdominal Wall Incision
Time frame: At the end of surgery
Time to First Postoperative Flatus
Time frame: Up to 30 days after surgery
Time to First Postoperative Defecation
Time frame: Up to 30 days after surgery
Time to First Postoperative Ambulation
Time frame: Up to 30 days after surgery
Time to First Postoperative Oral Intake
Time frame: Up to 30 days after surgery
Time to Meeting Discharge Criteria
Time frame: Up to 30 days after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
Related trials for STOMACH NEOPLASM
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Single-Port Robot-Assisted Radical Distal Gastrectomy and Multi-Port Robot-Assisted Radical Distal Gastrectomy in people with STOMACH NEOPLASM and Robotic Surgical Procedures, run by First Affiliated Hospital of Wenzhou Medical University at 5 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xian Shen, PhD (+86 139 6888 8872, shenxian1120@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With Technical Success of the Randomly Assigned Robotic Surgical Approach (time frame: At the end of surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.